Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | ABBV-CLS-484 |
Synonyms | |
Therapy Description |
ABBV-CLS-484 is a PTPN2/PTPN1 inhibitor, which activates JAK/STAT signaling, leading to remodeling of the tumor microenvironment, and potentially activation of an antitumor immune response and tumor growth inhibition (PMID: 37794185). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
ABBV-CLS-484 | ABBV CLS 484|ABBV CLS484|AC484 | ABBV-CLS-484 is a PTPN2/PTPN1 inhibitor, which activates JAK/STAT signaling, leading to remodeling of the tumor microenvironment, and potentially activation of an antitumor immune response and tumor growth inhibition (PMID: 37794185). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT04777994 | Phase I | ABBV-CLS-484 + unspecified PD-1 antibody ABBV-CLS-484 | A Phase 1 Study With ABBV-CLS-484 in Subjects With Locally Advanced or Metastatic Tumors | Recruiting | USA | ISR | FRA | ESP | 2 |